In Vitro & In Vivo Diagnostic Substances
Standard Industrial Classification: SIC 2835
Industry Insider Sentiment Analysis
The In Vitro & In Vivo Diagnostic Substances sector (SIC 2835) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-31 04:31 | 2024-01-26 | AWH | Aspira Women's Health Inc. | Sandford Nicole | Director, Officer | BUY | $0.00 | 2,400 | $0 | 61,103 |
| 2024-01-19 00:30 | 2024-01-16 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Officer | SELL | $56.01 | 341 | $19,099 | 58,744 |
| 2024-01-11 00:15 | 2024-01-08 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | Officer | SELL | $28.87 | 2,275 | $65,682 | 43,927 |
| 2024-01-06 00:50 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | Officer | SELL | $29.46 | 5,843 | $172,135 | 54,372 |
| 2024-01-06 00:50 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | Officer | SELL | $29.46 | 5,532 | $162,973 | 46,202 |
| 2024-01-06 00:46 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Hicks Derek | Officer | SELL | $29.46 | 3,877 | $114,216 | 36,987 |
| 2024-01-06 00:45 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | Officer | SELL | $29.46 | 3,805 | $112,095 | 51,474 |
| 2024-01-06 00:44 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | Officer | SELL | $29.50 | 4,608 | $135,954 | 40,845 |
| 2024-01-06 00:49 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Goddard Glenn | Officer | SELL | $29.46 | 5,365 | $158,053 | 40,585 |
| 2024-01-06 00:51 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Director, Officer | SELL | $29.46 | 19,223 | $566,310 | 846,486 |
| 2024-01-03 18:41 | 2024-01-02 | VNRX | VOLITIONRX LTD | Eight Corp Ltd | 10% owner | SELL | $0.90 | 20,000 | $18,000 | 298,419 |
| 2023-12-20 18:31 | 2023-12-15 | VNRX | VOLITIONRX LTD | Eight Corp Ltd | 10% owner | SELL | $0.75 | 20,000 | $15,000 | 318,419 |
| 2023-12-19 18:59 | - | VNRX | VOLITIONRX LTD | Butera Salvatore Thomas | Officer | BUY | $0.83 | 10,000 | $8,300 | 99,350 |
| 2023-12-20 01:00 | 2023-12-15 | LNTH | Lantheus Holdings, Inc. | Marshall Robert J. Jr. | Officer | SELL | $78.24 | 10,000 | $782,400 | 103,170 |
| 2023-12-18 17:38 | - | VNRX | VOLITIONRX LTD | Butera Salvatore Thomas | Officer | BUY | $0.77 | 10,000 | $7,700 | 89,350 |
| 2023-12-16 00:30 | 2023-12-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Officer | SELL | $75.62 | 341 | $25,786 | 59,085 |
| 2023-12-14 17:11 | - | VNRX | VOLITIONRX LTD | Rootsaert Rodney Gerard | Officer | BUY | $0.60 | 10,000 | $6,000 | 78,652 |
| 2023-12-11 16:51 | - | VNRX | VOLITIONRX LTD | Reynolds Cameron John | Director, Officer | BUY | $0.67 | 10,000 | $6,700 | 1,704,518 |
| 2023-12-09 01:28 | 2023-12-06 | AWH | Aspira Women's Health Inc. | Merchant Minh Hoang | Officer | SELL | $3.37 | 980 | $3,303 | 0 |
| 2023-12-09 01:00 | 2023-12-07 | IDXX | IDEXX LABORATORIES INC /DE | POLEWACZYK JAMES F | Officer | OPT+S | $521.79 | 11,636 | $6,071,501 | 10,050 |
| 2023-12-07 01:21 | 2023-12-06 | AWH | Aspira Women's Health Inc. | Sandford Nicole | Director, Officer | BUY | $3.36 | 5,000 | $16,800 | 58,703 |
| 2023-12-07 01:01 | 2023-12-04 | IDXX | IDEXX LABORATORIES INC /DE | MAZELSKY JONATHAN JAY | Director, Officer | OPT+S | $513.05 | 7,128 | $3,657,049 | 79,233 |
| 2023-12-06 00:19 | 2023-12-01 | MYGN | MYRIAD GENETICS INC | Riggsbee Richard Bryan | Officer | SELL | $19.09 | 30,000 | $572,835 | 291,812 |
| 2023-12-02 01:44 | 2023-11-30 | TKNO | Alpha Teknova, Inc. | Gelhaus Ken | Officer | BUY | $1.73 | 3,587 | $6,220 | 22,924 |
| 2023-11-28 17:39 | - | VNRX | VOLITIONRX LTD | Innes Guy Archibald | Director | BUY | $0.77 | 20,000 | $15,400 | 627,161 |
| 2023-11-28 17:39 | - | VNRX | VOLITIONRX LTD | Futcher Edward | Director | BUY | $0.80 | 9,000 | $7,200 | 71,936 |
| 2023-11-27 18:28 | - | VNRX | VOLITIONRX LTD | Innes Guy Archibald | Director | BUY | $0.76 | 10,000 | $7,600 | 607,161 |
| 2023-11-24 19:06 | - | VNRX | VOLITIONRX LTD | Innes Guy Archibald | Director | BUY | $0.71 | 20,000 | $14,200 | 597,161 |
| 2023-11-21 00:30 | 2023-11-16 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Officer | SELL | $67.96 | 1,500 | $101,940 | 88,651 |
| 2023-11-17 18:01 | - | VNRX | VOLITIONRX LTD | Butera Salvatore Thomas | Officer | BUY | $0.81 | 10,000 | $8,100 | 79,350 |
| 2023-11-16 00:32 | 2023-11-13 | LNTH | Lantheus Holdings, Inc. | Heino Mary Anne | Director, Officer | SELL | $63.72 | 11,780 | $750,611 | 317,687 |
| 2023-11-16 00:30 | 2023-11-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Officer | SELL | $63.57 | 341 | $21,677 | 59,426 |
| 2023-11-04 00:12 | 2023-11-01 | MYGN | MYRIAD GENETICS INC | Riggsbee Richard Bryan | Officer | SELL | $15.69 | 30,000 | $470,622 | 321,812 |
| 2023-11-03 20:59 | 2023-11-03 | NEOG | NEOGEN CORP | BOEHM WILLIAM T | Director | BUY | $16.06 | 2,000 | $32,110 | 26,509 |
| 2023-11-02 23:42 | 2023-10-31 | NTLA | Intellia Therapeutics, Inc. | Bhanji Muna | Director | SELL | $23.90 | 265 | $6,334 | 11,996 |
| 2023-10-26 15:01 | 2023-10-25 | NEOG | NEOGEN CORP | Jones Douglas Edward | Officer | BUY | $15.17 | 10,000 | $151,727 | 36,131 |
| 2023-10-17 17:06 | 2023-10-13 | NEOG | NEOGEN CORP | Lilly Jason Warren | Officer | SELL | $15.10 | 351 | $5,300 | 26,744 |
| 2023-10-14 00:03 | 2023-06-02 | LNTH | Lantheus Holdings, Inc. | Baylor-Henry Minnie | Director | SELL | $86.22 | 6 | $517 | 16 |
| 2023-10-12 18:25 | 2023-10-11 | NEOG | NEOGEN CORP | Lilly Jason Warren | Officer | SELL | $15.69 | 1,917 | $30,087 | 25,944 |
| 2023-10-12 23:01 | 2023-10-12 | NEOG | NEOGEN CORP | Tobin James P | Director | BUY | $15.19 | 3,000 | $45,567 | 20,392 |
| 2023-10-12 18:54 | 2023-10-11 | NEOG | NEOGEN CORP | BOEHM WILLIAM T | Director | SELL | $15.61 | 2,591 | $40,456 | 24,509 |
| 2023-10-11 23:21 | 2023-10-11 | NEOG | NEOGEN CORP | Naemura David H. | Officer | BUY | $15.03 | 10,000 | $150,333 | 10,000 |
| 2023-09-22 00:04 | 2023-09-19 | TKNO | Alpha Teknova, Inc. | Terrill Damon | Officer | BUY | $1.85 | 27,027 | $50,000 | 41,027 |
| 2023-09-22 00:03 | 2023-09-19 | TKNO | Alpha Teknova, Inc. | Lowell Matthew | Officer | BUY | $1.85 | 54,054 | $100,000 | 88,054 |
| 2023-09-22 00:03 | 2023-09-19 | TKNO | Alpha Teknova, Inc. | Gunstream Stephen | Director, Officer | BUY | $1.85 | 54,054 | $100,000 | 162,852 |
| 2023-09-22 03:58 | 2023-09-19 | TKNO | Alpha Teknova, Inc. | Telegraph Hill Partners IV, L.P. | 10% owner | BUY | $1.85 | 8,108,107 | $14,999,998 | 3,761,132 |
| 2023-09-22 00:04 | 2023-09-19 | TKNO | Alpha Teknova, Inc. | MACKOWSKI J MATTHEW | Director | BUY | $1.85 | 810,810 | $1,499,999 | 810,810 |
| 2023-09-19 23:05 | - | VNRX | VOLITIONRX LTD | Henshall Mickie | Director | BUY | $1.25 | 3,706 | $4,633 | 18,706 |
| 2023-09-19 23:30 | 2023-09-15 | LNTH | Lantheus Holdings, Inc. | Niedzwiecki Daniel | Officer | OPT+S | $66.43 | 2,846 | $189,060 | 66,295 |
| 2023-09-13 01:37 | 2023-09-08 | AWH | Aspira Women's Health Inc. | Hombeck Torsten | Officer | BUY | $4.30 | 2,246 | $9,658 | 3,000 |
Sector-Wide Insider Alpha
Analyzing insider movements across the In Vitro & In Vivo Diagnostic Substances sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2835) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in In Vitro & In Vivo Diagnostic Substances
Every transaction in the In Vitro & In Vivo Diagnostic Substances industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.